Page 4 | Certara

Publication

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

This review article examines the development of radiopharmaceutical imaging agents and radioligand therapies for pediatric…

CertaraMarch 26, 2026

Blog

Shaping the Future of Medical Writing: Key Themes for 2026

Five key themes and their implications for leaders shaping their Medical Writing strategy for 2026

CertaraMarch 26, 2026

eBook

The Next Lap in Global Regulatory Submission Speed: Advanced Approaches to Excellence and Acceleration

Discover advanced regulatory writing strategies, global regulatory submission best practices, eCTD guidance, ICH M15 updates…

CertaraMarch 26, 2026

On-Demand Webinar

Portfolio Prioritization for Large and Small Pharma Using Early-Stage Biosimulation

Learn how early-stage biosimulation and mechanistic modeling enable smarter portfolio prioritization before IND-enabling studies. Watch…

CertaraMarch 25, 2026

Publication

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

This publication highlights how pharmacometric modeling, supported by Certara, was used to inform dose selection…

CertaraMarch 25, 2026

Publication

Model-Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC: A QSP Model for Alpelisib and Tipifarnib Combination

This study showcases how quantitative systems pharmacology (QSP) and model-informed drug development (MIDD) can transform…

Danielle PillsburyMarch 25, 2026

Blog

Interactive Global Value Dossiers: turning evidence into market access impact

Learn how an interactive global value dossier improves stakeholder engagement and streamlines value dossier preparation…

CertaraMarch 25, 2026

On-Demand Webinar

Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs)

Watch this on-demand webinar to learn how model-informed strategies using PopPK, PBPK, and QSP can…

CertaraMarch 25, 2026

Blog

Why the Most Important Phase 3 Decisions Should Be Made Before Phase 3

Learn how advanced modeling for reimbursement strategy using MBMA and QSP strengthens payer evidence and…

CertaraMarch 24, 2026

Press Coverage Video

Building Smarter Trials With Bayesian Statistics

Learn how Bayesian statistics are transforming clinical trials with adaptive designs, faster insights, and more…

CertaraMarch 24, 2026

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

Shaping the Future of Medical Writing: Key Themes for 2026

The Next Lap in Global Regulatory Submission Speed: Advanced Approaches to Excellence and Acceleration

Portfolio Prioritization for Large and Small Pharma Using Early-Stage Biosimulation

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

Model-Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC: A QSP Model for Alpelisib and Tipifarnib Combination

Interactive Global Value Dossiers: turning evidence into market access impact

Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs)

Why the Most Important Phase 3 Decisions Should Be Made Before Phase 3

Building Smarter Trials With Bayesian Statistics

Newsletter sign up

Quick links

Solutions

Contact